Clinical trials are the structured research studies that determine whether a new drug, device, or medical procedure actually works and is safe enough to use. The process is more rigorous than most people realize — a typical new drug spends many years, often on the order of a decade or more, in development, costs a great deal to bring to market, and most candidates fail somewhere along the way. Understanding how do clinical trials work matters whether you are considering enrolling in one, hoping a new treatment becomes available, or simply trying to make sense of medical news. This guide walks through the phases, the participant experience, the regulatory and ethical framework, and the practical considerations of joining a study. It is general education, not medical advice; whether a specific trial is right for you is a decision to make with your own doctor.
For related background on navigating care and conditions, see our medical conditions resource hub.
What clinical trials are designed to answer
A clinical trial is a research study with human participants that tests a specific question: does this drug lower cholesterol better than the current standard? Does this device reduce stroke risk? Is this surgical technique safer than the existing approach? Each trial has a primary endpoint — the specific outcome the study is designed to measure — and the study is structured to produce statistically meaningful evidence about that endpoint.
Clinical trials differ from observational studies, which track what happens to patients without intervening. In a trial, researchers actively assign participants to treatments and follow strict protocols to control for variables. That structure is what allows trials to produce evidence strong enough to support regulatory approval and changes to medical practice. Trials are also different from the care you receive from your own doctor: the goal of a trial is to answer a research question, which is related to, but not the same as, treating one individual patient.
The four phases of clinical trials
Drug development follows a standardized phase structure regulated by the FDA. The participant numbers below are typical ranges and vary widely by disease and study design:
Phase 1: First testing in humans, often roughly 20 to 100 participants (sometimes healthy volunteers, sometimes patients). The goal is safety and dosing — identifying side effects and finding doses that are tolerable. Phase 1 trials commonly take about a year or more.
Phase 2: Tests effectiveness in a larger group — often on the order of 100 to 300 patients with the target condition. Researchers look for early signals that the treatment works while continuing to monitor safety. Phase 2 typically lasts one to two years.
Phase 3: Large-scale efficacy and safety testing, frequently in hundreds to a few thousand patients across multiple sites. The treatment is compared with an existing standard or a placebo. Phase 3 often takes two to four years and produces much of the data the FDA reviews for approval.
Phase 4: Post-marketing surveillance after approval. It tracks long-term safety, rare side effects, and effectiveness in the broader, real-world population, and can continue for years. Some phase 4 studies are required by regulators as a condition of approval.
Not every product follows this exact path. Vaccines, medical devices, behavioral interventions, and some cancer therapies use adapted designs, and expedited pathways can compress the timeline for treatments that address serious unmet needs.
How participants are selected
Each trial has eligibility criteria — inclusion criteria (characteristics that qualify a participant) and exclusion criteria (characteristics that disqualify). For a type 2 diabetes drug trial, inclusion criteria might be a certain age range, an A1c within a defined window, and a BMI range. Exclusion criteria might include type 1 diabetes, a recent heart attack, significant kidney disease, or pregnancy.
These criteria are designed to produce a reasonably consistent study population so the results are interpretable. Strict criteria limit who can participate but reduce variables that could obscure the treatment’s effect. Looser criteria produce results more applicable to the real-world population but can add noise to the data. If you do not qualify for one trial, you may qualify for another, so it is worth checking more than one study.
Randomization and blinding
Most Phase 2 and Phase 3 trials use randomization — participants are randomly assigned to either the experimental treatment or a control (a placebo or the existing standard of care). Randomization reduces selection bias and allows the trial to produce statistically meaningful comparisons.
Blinding is the related practice of keeping participants and/or the research team from knowing which group each participant is in. A “double-blind” trial means neither the participant nor the treating clinician knows the assignment until the study is unblinded. Blinding helps prevent the placebo effect and observer bias from distorting the results. Together, randomization and blinding are considered the gold standard for clinical research — though not every ethical or practical trial can use them.
Informed consent: your rights as a participant
Informed consent is central to ethical research and is more than signing a form. Before you enroll, the research team must explain the study’s purpose, what will happen, how long it will take, the reasonably foreseeable risks and possible benefits, alternatives to participating (including standard treatment outside the trial), and how your privacy will be handled. You should have time to ask questions and to discuss the study with your own doctor or family.
Participation is voluntary, and you can withdraw at any time, for any reason, without penalty and without losing access to your regular medical care. Consent is also ongoing: if new risks emerge during the study, the team is expected to tell you, and you can reconsider. If anything in a consent document is unclear, ask until it makes sense before agreeing.
What participants actually experience
Participating in a clinical trial typically involves:
- An initial screening visit with a detailed medical history, physical exam, and lab tests to confirm eligibility
- An informed consent process where the trial’s purpose, procedures, risks, and benefits are explained
- Random assignment to a treatment group (in randomized trials)
- Regular study visits — often every few weeks during active treatment
- Treatment with the study intervention, a placebo, or a comparator
- Lab work, imaging, questionnaires, and other measurements at each visit
- Follow-up visits after the active treatment period ends
- Sometimes long-term follow-up extending months or years
The total time commitment varies enormously — some trials require only a few visits over a few months, while others involve frequent visits for years. The consent process should spell out what will be asked of you.
Compensation and costs
Participants in clinical trials are generally not charged for the experimental treatment, study-specific visits, or trial-related procedures; these are usually covered by the trial sponsor. Some trials also cover travel and lodging for participants who live far from the study site. It is reasonable to ask, in advance and in writing, exactly what is covered.
Compensation for participants varies widely. Phase 1 healthy-volunteer studies, which can involve multi-day inpatient stays, sometimes pay more substantial amounts for the time commitment, while patient-focused Phase 2 and 3 trials more often provide modest per-visit compensation, primarily for time and travel rather than as payment for taking a risk.
Your routine medical care and insurance continue separately. Care that would happen anyway (regular doctor visits, standard medications) is typically still billed to insurance, and coverage rules for “routine costs” in trials can be complex. Confirming who pays for what before you enroll can prevent surprises; our healthcare costs guide explains how medical billing generally works.
The regulatory and ethical framework — FDA and IRB
Clinical trials in the U.S. operate under multiple layers of oversight. The FDA reviews the protocol for a regulated product before human testing begins (through an Investigational New Drug application) and reviews the resulting data when a sponsor seeks approval to market it. That is oversight at the federal regulatory level.
An Institutional Review Board (IRB) — also called an ethics committee — reviews the trial to protect participants’ rights and welfare. The IRB reviews the consent materials, the protocol’s risk–benefit balance, and safeguards for vulnerable participants, and it must approve a study before enrollment and continue to monitor it. Many trials also have an independent data and safety monitoring board that can pause or stop a study early if the data warrant. These protections grew out of past research abuses and the ethical principles later codified in documents such as the Belmont Report.
Where to find clinical trials
The federal database ClinicalTrials.gov, maintained by the U.S. National Library of Medicine, lists registered clinical trials in the U.S. and many international studies. Searching by condition produces lists of trials with locations, eligibility criteria, recruiting status, and contact information. The NIH also offers plain-language resources on what to consider before joining a study.
For specific conditions, professional societies and patient-advocacy organizations often maintain curated lists, and major academic medical centers are common trial sites for cancer and rare-disease studies. A good next step is to bring any trial you are considering to your own doctor, who can help you weigh it against standard care. For a starting point on finding studies for specific conditions, see our how to find clinical trials guide, and note that telehealth is increasingly used for some study visits.
Frequently Asked Questions
Are clinical trial drugs safe?
Investigational drugs have passed extensive laboratory and animal testing, but their safety in larger human populations is still being established, which is the point of the trial. Phase 1 studies carry more uncertainty than Phase 3 studies, where the drug has already been tested in earlier human trials. The consent process is where the known and possible risks should be explained to you.
Can I leave a clinical trial early?
Yes. Participation is voluntary, and you can withdraw at any time for any reason. The informed consent process emphasizes this right, and withdrawing should not affect your standard medical care. Telling the study team is helpful so they can arrange any needed safety follow-up.
Will I get the actual drug or a placebo?
In randomized placebo-controlled trials, you may receive the placebo; the probability depends on the design (often a 50/50 split in two-arm studies). Many trials do not use a placebo alone when withholding effective treatment would be unethical — instead, the new treatment is compared with the current standard of care.
Are clinical trials only for serious illnesses?
No. Trials cover everything from common conditions (such as allergies or heartburn) to severe and rare diseases, as well as prevention, devices, and behavioral interventions. The research process applies regardless of the condition.
How long does drug development take?
From initial discovery to approval, the process commonly spans well over a decade. The human phases (1 through 3) often take several years, and regulatory review adds more time. Expedited pathways (such as breakthrough therapy or fast track designations) can shorten parts of this for treatments that address serious unmet needs.
Is joining a trial a replacement for seeing my doctor?
No. A clinical trial is one option to consider alongside standard care, not a substitute for it. Discuss any trial with your treating clinician, who can help you understand how it fits your situation and what happens to your usual care while you participate.
The bottom line on how clinical trials work
Clinical trials are the structured process that determines whether new medical treatments work and are safe. The four-phase system, randomization, blinding, informed consent, and IRB and FDA oversight combine to produce evidence rigorous enough to change medical practice — and to protect the people who volunteer. For participants, joining a trial can mean access to promising treatments, a structured experience with regular monitoring, and a contribution to medical knowledge; it can also mean receiving a placebo and accepting some uncertainty. Understanding the framework helps anyone considering participation, hoping for new treatments, or following medical research news. If you are weighing a specific study, the best next step is a conversation with your own doctor.
Note: This article is general education about the clinical trial process, not medical advice or a recommendation to join or avoid any study. Participation is voluntary and protected by informed consent — you may ask questions and withdraw at any time — and every regulated trial is overseen by an IRB and, for drugs and devices, the FDA. A trial is one option to weigh alongside standard care, not a substitute for it. Before enrolling, review the risks, benefits, costs, and alternatives with the study team and with your own doctor.
Sources
- U.S. Food and Drug Administration (FDA) — Drug Development Process; Clinical Research (Step 3)
- National Institutes of Health (NIH) and the NIH Clinical Center — Participating in Clinical Trials; NIH Clinical Research Trials and You
- ClinicalTrials.gov (U.S. National Library of Medicine) — trial registry and background resources
- U.S. Office for Human Research Protections (OHRP) — informed consent and IRB oversight; the Belmont Report